David P Sullivan

6883020, Apr 19, 2005

Jun 26, 1997

08/883241

Edward James Taranto - Boston MA, US
William Joseph Gauvin - Leominster MA, US
Ursula Smith - Acton MA, US
David J. Sullivan - Nashua NH, US
Louise Lemaire - Newburyport MA, US

Hewlett-Packard Development Company, L.P. - Houston TX

G06F015/16

709213, 709219, 709229, 707 10

A process and apparatus for storing, in non-volatile memory of a local computer system, a selected remote web page and all web pages in a preselected number of nodes below the selected web page. The stored web pages may be filtered to cause the local computer system to store only web pages that are not larger than a preselected size, or web pages that are stored on the same remote network device.

8506944, Aug 13, 2013

Oct 23, 2009

12/605024

Benjamin Sullivan - San Diegao CA, US
Tannin A. Schmidt - Calgary, CA
David A. Sullivan - Boston MA, US

The Regents of the University of California - Oakland CA
Schepens Eye Research Institute - Boston MA

A61P 27/02
A61K 38/48
C12N 9/50

424 7804, 424 9463, 435219, 514 208

An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.

56209215, Apr 15, 1997

Sep 21, 1993

8/124842

David A. Sullivan - Acton MA

The Schepens Eye Research Institute, Inc. - Boston MA

A61K 3156

514178

The topical application to the ocular surface or adjacent regions of the eye of a preparation containing a therapeutic amount of an androgen or androgen analogue is disclosed as a method of relieving the chronic and acute manifestation of dry eye symptoms in Sj ogren's syndrome.

43634079, Dec 14, 1982

Jan 22, 1981

6/227477

Sheldon A. Buckler - Brookline MA
Jeffrey B. Burns - Natic MA
Alfredo G. Kniazzeh - West Newton MA
Paul A. Plasse - Lexington MA
David J. Sullivan - Bolton MA

Polaroid Corporation - Cambridge MA

B07C 502
B07C 5344

209 33

A method and system for testing and sorting a production run of sheet-like batteries includes: testing each battery to obtain a first value of electrical energy; placing machine readable indicia on each battery corresponding to the first value; retesting each battery after passage of a period of time to obtain a second value of electrical energy; machine reading the indicia and computing the rate of decay of electrical energy for each battery as a function of the difference between said first and second values per unit time; and sorting the batteries in accordance with the computed rate of decay to separate those batteries having an acceptable rate of decay from those batteries having too great a rate of decay.

59589124, Sep 28, 1999

Nov 17, 1997

8/971768

David A. Sullivan - Acton MA

The Schepens Eye Research Institute, Inc. - Boston MA

A61K 3133

514177

The topical application to the ocular surface or adjacent regions of the eye of a preparation containing a therapeutically effective amount of an androgen or androgen analogue or a therapeutically effective amount of TGB-. beta. is disclosed as a method of relieving the chronic and acute manifestation of dry eye signs and symptoms in keratoconjunctivitis sicca (KCS), for example in Sjogren's syndrome. Measurement of the increased tear levels of TGF-. beta. is disclosed as a diagnostic test to monitor the therapeutic effect of topical treatment with androgen or androgen analogues.

56887655, Nov 18, 1997

Jun 7, 1995

8/477301

David A. Sullivan - Acton MA

The Schepens Eye Research Institute, Inc. - Boston MA

A61K 3700

514 12

The topical application to the ocular surface or adjacent regions of the eye of a preparation containing a therapeutic amount of an androgen or androgen analogue or a therapeutic amount of TGF-. beta. is disclosed as a method of relieving the chronic and acute manifestation of dry eye symptoms in Sjogren's syndrome. Measurement of the increased tear levels of TGF-. beta. is disclosed as a diagnostic test to monitor the therapeutic effect of topical treatment with androgen or androgen analogues.

61072893, Aug 22, 2000

Mar 17, 1999

9/271600

David A. Sullivan - Acton MA

The Schepens Eye Research Institute, Inc. - Boston MA

A61K 3156

514178

The topical application, at a dose rate less than or equal to 0. 1 mg day, to the ocular surface or adjacent regions of the eye of a preparation containing a therapeutically effective amount of an androgen or androgen analogue or a therapeutically effective amount of TGF-. beta. is disclosed as a method of relieving the chronic and acute manifestation of dry eye signs and symptoms in keratoconjunctivitis sicca (KCS), for example in Sjogren's syndrome.

20220323278, Oct 13, 2022

Apr 7, 2021

17/224527

David Sullivan - Bryantville MA, US

A61G 7/015
A61G 7/075

A face-down lounge chair apparatus for comfortable face-down lounging includes a chair frame and a pair of legs coupled to the chair frame. A covering is coupled to the chair frame and has a face aperture extending from a covering top side through a covering bottom side proximal a head distal portion of the chair frame. A face pad is coupled to the covering top side around a perimeter of the face aperture. A drop-down tray is coupled to the covering. The drop-down tray has a plurality of straps coupled to the covering bottom side proximal the face aperture and a tray body adjustably coupled to the plurality of straps to go from a proximal position adjacent the covering to an extended position in parallel opposition to the covering bottom side.